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Abstract Guanylyl cyclase C (GC-C), a member of mem-
brane-bound guanylyl cyclases, is a receptor protein for guany-
lin and uroguanylin. The binding of a ligand to the extracellular
domain of GC-C (ECDGCC) triggers signal transduction, re-
sulting in the regulation of intestinal £uids and electrolytes. A
previous study proposed that a ligand-binding site on GC-C is
localized near the transmembrane region. To further investigate
the mechanism by which GC-C is activated, the C-terminal
polypeptide (Met341^Gln407) of ECDGCC (the micro domain),
which includes the ligand-binding site, was over-expressed in
Escherichia coli and its ligand-binding ability was examined.
The micro domain showed ligand-binding activity (IC50 =
1U1038 M). This result clearly indicates that a ligand-binding
site is located in close proximity to the membrane-bound region,
and that the micro domain is capable of independently binding
the ligand, without assistance from other domains. The use of
this micro binding domain in the study of interactions between
GC-C and ligands could be a useful tool and could lead to a
better understanding of GC-C signal transduction. / 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Guanylyl cyclase C (GC-C) is a membrane-bound protein,
which consists of an N-terminal extracellular domain
(ECDGCC), a transmembrane domain, and a C-terminal in-
tracellular domain [1,2]. ECDGCC is responsible for the li-
gand binding, resulting in the activation of the catalytic do-
main and, ultimately, the regulation of intestinal £uids and
electrolytes, via the cystic ¢brosis transmembrane conduc-
tance regulator protein [3]. GC-C is stimulated by several li-
gands, including the endogenous peptide hormones, guanylin
and uroguanylin, and heat-stable enterotoxin (STa), the exog-
enous ligand [4^10]. Previously, we reported that a ligand-
binding site is located at the region between Ser387 and
Lys393, near the transmembrane domain [11]. This result
poses the question of the minimum peptide region required
to recognize the ligand.
Guanylyl cyclase A (GC-A), which is thought to have a
tertiary structure similar to GC-C, is a member of the mem-
brane-bound guanylyl cyclase family and is a receptor protein
for atrial natriuretic peptide [12]. Recently an analysis of the
crystal structure of the extracellular domain (ECDGCA) of
GC-A revealed that ECDGCA consists of two subdomains,
the N-terminal K-helical and the C-terminal L-sheet domains
[12]. The identity of the region of the amino acid residues
between GC-A and GC-C is about 10%, but that of the C-ter-
minal regions of ECDGCC and ECDGCA, which corresponds
to the L-sheet domain of ECDGCA, is relatively high (23%),
as shown in Fig. 1. In addition, a secondary structure predic-
tion of ECDGCC implies that the secondary structure of the
C-terminal region of ECDGCC consists of L-strands, which
contain the ligand-binding site and is located in the same rel-
ative region as that of the C-terminal region of ECDGCA, as
shown in Fig. 1 [13]. Therefore, we speculate that the tertiary
structure of the C-terminal region of ECDGCC, referred to as
the micro domain, is similar to that of the C-terminal region
of ECDGCA and that the micro domain might possess the
ability to bind the ligand, without assistance from other do-
mains.
Based on this hypothesis, the C-terminal polypeptide of
ECDGCC (the micro domain) was prepared and its ligand-
binding ability examined. Based on the ¢ndings herein, the
micro domain itself has a tertiary structure that is capable
of binding the ligand. The data obtained permit a better
understanding of the nature of signal transduction of GC-C.
2. Materials and methods
2.1. Materials
Restriction enzymes were purchased from Toyobo (Osaka, Japan)
and New England BioLabs, Inc. (Beverly, MA, USA). Taq polymer-
ase and T4 DNA ligase were obtained from Takara Shuzo Co. (Kyo-
to, Japan). STp(4^17) (porcine STa with the amino acid sequence
from positions 4 to 17) and 125I-ANB-STp(4^17) were prepared ac-
cording to a previously described procedure [14,15]. All other chem-
icals and solvents were of reagent grade. Polymerase chain reaction
(PCR) was carried out using a Sanyo DNA ampli¢er MIR-D30 (Osa-
ka, Japan).
2.2. Construction of the expression vector of the micro domain for the
expression by Escherichia coli cells
The cDNA encoding the extracellular domain (Ser1^Gln407) of
porcine GC-C(C349A), in which the Cys349 residue was mutated to
an Ala residue, was prepared according to a previously reported meth-
od [14,15] using primers for the mutation (sense, ACTTTGGA-
CAACGCCGGGGATATTGAC; antisense, GTCAATATCCCCG-
GCGTTGTCCAAAGT). The cDNA was inserted into pVL1392
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(Invitrogen) at the PstI and the BamHI sites, resulting in the con-
struction of pVL-ECD(C349A). The cDNA encoding the micro do-
main (Met341^Gln407) was subcloned into the pET17b expression
vector (Novagen), following the introduction, by means of PCR, of
an NdeI site at its 5P end and a XhoI site at its 3P end using pVL-
ECD(C349A) as a template. The resulting expression vector, referred
to as pY42, contained the cDNA which encoded the extra amino acid
residues GHHHHHH at the C-terminus of the micro domain
(Met341^Gln407). The cDNA sequences of the vectors were con-
¢rmed by analysis using the ABI PRISM1310 Genetic Analyzer
(PE Applied Biosystems).
2.3. Expression of the micro domain by E. coli cells
E. coli BL21(DE3) cells, transformed with the expression vector
pY42, were cultured at 37‡C in Luria broth supplemented with ampi-
cillin (50 mg/l). Expression of the mutant protein was induced by the
addition of 1 mM isopropyl L-thiogalactopyranoside (IPTG) at the
mid-log phase of cell growth. After incubation at 37‡C for 3 h, the
cells were harvested and washed with PBS(3) containing 1 mM phen-
ylmethylsulfonyl £uoride. The cells were resuspended in the same
bu¡er, sonicated on ice, and centrifuged (15 000Ug, 20 min). The
resulting precipitates were incubated with 10 mM dithiothreitol in
50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris^HCl)
(pH 8.0) containing 6 M guanidine^HCl at 50‡C for 30 min. The
protein was ¢rst puri¢ed by means of Cosmosil 140C18-OPN (Nacarai
Tesque Inc., Kyoto, Japan), as described previously [9]. The mutant
protein was ¢nally puri¢ed by high performance liquid chromatogra-
phy (HPLC), as described previously [9], and lyophilized. The protein
thus prepared was characterized by mass spectrometry and amino acid
analysis, as described previously [7].
2.4. In vitro refolding of the mutant protein
The puri¢ed protein (1 nmol) was dissolved in 0.05% tri£uoroacetic
acid (TFA) (20 Wl) and mixed with nine volumes of 50 mM Tris^HCl
(pH 7.4) or 50 mM AcONa (pH 4.7), followed by incubation at room
temperature for 1 h. The reaction mixture was centrifuged (15 000Ug,
20 min), and the resulting precipitants and supernatants were ana-
lyzed by SDS^polyacrylamide gel electrophoresis (PAGE). The reac-
tion mixture was also analyzed by HPLC, as described previously [9].
2.5. Photoa⁄nity labeling of the micro domain with
125I-ANB-STp(4^17) and a binding assay
The refolded protein (0.1 nmol) was mixed with 125I-ANB-STp-
(4^17) (4U104 cpm) in the presence or absence of STp(4^17) (¢nal
concentration, 1035 M), which showed the same GC-C binding a⁄n-
ity as native STp [2], and incubated at 37‡C for 1 h in a ¢nal volume
of 60 Wl of PBS(3), using a previously reported method [14,15]. The
solution, in an ice bath, was then exposed to UV radiation (302 nm,
model UVM-57, UVP Inc., CA, USA) for 30 min. The reaction mix-
ture was subjected to SDS^18% PAGE. The photoa⁄nity-labeled
protein was analyzed by autoradiography on a Fujix Bio-image ana-
lyzer BAS 2000 (Fuji ¢lm, Tokyo, Japan).
To estimate the ligand-binding a⁄nity of the micro domain, we
attempted to separate free 125I-ANB-STp(4^17) and 125I-ANB-
STp(4^17), which binds to the micro domain, by gel ¢ltration or
Ultrafree ¢lter (Millipore). However, it was di⁄cult to completely
separate the free ligand from the micro domain using our system.
Therefore, the ligand-binding ability was estimated by the autoradiog-
raphy on SDS^PAGE. A competitive binding assay was performed in
the presence of several concentrations of STp(4^17) under the condi-
tions described above. The reaction mixture was separated by SDS^
PAGE, and the radioactivity of the photoa⁄nity-labeled micro do-
main on the gel was quanti¢ed by the Fujix Bio-image analyzer BAS
2000.
3. Results and discussion
Ligand binding to the ECDGCC triggers the signal trans-
duction of GC-C, resulting in the activation of the intracel-
lular catalytic domain of GC-C. In our previous study, we
proposed that the ligand-binding site is located in the region
between Ser387 and Lys393 in ECDGCC, near the transmem-
brane domain [11]. Therefore, this region should supply the
speci¢c tertiary structure required for the ligand binding.
However, the tertiary structure of the entire and the essential
ligand-binding domain of ECDGCC has not yet been re-
ported.
Previously, ECDGCC was prepared using a system consist-
ing of baculovirus and insect cells in order to obtain structural
information on the ligand binding of ECDGCC [14]. How-
ever, the expression e⁄ciency of the recombinant ECDGCC
by the baculovirus expression system was low, and the protein
aggregated readily after puri¢cation. In addition, it is gener-
ally known that small peptide fragments of receptor proteins,
such as the peptide fragment consisting of seven amino acid
residues from Ser387 to Lys393 of ECDGCC, cannot fold into
the native conformation su⁄cient to bind to the ligand.
Therefore, the minimum functional binding domain of
ECDGCC was explored in order to further study the interac-
tion between ECDGCC and ligands.
A recent X-ray crystallographic structural analysis of
ECDGCA indicated that the C-terminal region of ECDGCA
is folded into a L-sheet structure [12]. The sequence alignment
of ECDGCC and ECDGCA showed that these proteins
shared a 23% homology at the C-terminal region (from
Met341 to Gln407 of GC-C), as shown in Fig. 1, implying
that the tertiary structure of the C-terminal region of
ECDGCC, referred to as the micro domain, might be the
same as that of ECDGCA. The region between the Phe376
and the Ala403 residues of ECDGCA, which corresponds to
the region between the Met356 and the Pro383 residues of
ECDGCC (Fig. 1), is comprised of a L-sheet domain in the
crystal structure of ECDGCA. In the case of ECDGCC, this
region contains the ligand-binding site, suggesting that this
domain should be included as a ligand-binding unit of GC-
C. In addition, our previous study indicated that the Asp347
and Asn348 residues of GC-C play an important role in the
ligand binding of GC-C [16]. Moreover, the sequence between
Gly342 and Leu346 is completely conserved in GC-Cs from
several species, also implying that it plays a signi¢cant role in
ligand binding. The N-terminal Met341 residue is also in-
cluded since the Met residue is generated by the starting co-
don in the E. coli expression system used in this study. There-
fore, the micro domain (Met341 to Gln407) was prepared and
its ligand-binding ability examined, in an attempt to better
understand the nature of the essential ligand-binding domain.
The region between the Met341 and the Gln407 residues of
ECDGCC contains one cysteine residue at position 349. This
Fig. 1. Primary and secondary structures of the C-terminal region of ECDGCA and ECDGCC. Completely matched amino acid residues are
shown as dotted. ST denotes the secondary structure. The e and t in the secondary structure represent the L-sheet and the L-turn, respectively.
The secondary structure of GC-A was inferred from PDB and that of GC-C was predicted by the Chou^Fasman’s method [13].
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Cys349 residue is not found in other species of GC-C, suggest-
ing that it may not play a role in ligand binding. To avoid the
formation of an intermolecular disul¢de bond at the Cys349
residue, it was mutated to an Ala residue. For this purpose,
mutant C349A of the entire ECDGCC was ¢rst prepared and
its ligand-binding ability examined, using a previously re-
ported method [14]. The mutant C349A of ECDGCC showed
a ligand-binding ability identical to that of wild-type
ECDGCC (Fig. 2), indicating that the Cys349 is not abso-
lutely required for the binding of GC-C with ligands.
The cDNA encoding the micro domain, in which the
Cys349 residue was mutated to an Ala residue, was generated
by PCR using the cDNA encoding the mutant C349A of
ECDGCC as a template, and was inserted into the expression
vector, pET17b (Novagen), resulting in the construction of
the expression vector pY42. The micro domain was expressed
as an inclusion body in E. coli BL21(DE3) cells transformed
with pY42, as shown in Fig. 3A. Therefore, the micro domain
was puri¢ed by HPLC in a denatured form (Fig. 3B). The
puri¢ed micro domain showed a signal at m/z=8498.4, con-
sistent with its mass value (8498.1) calculated from the amino
acid sequence, in a mass spectrometric analysis by matrix-
assisted laser desorption/ionization time-of-£ight mass spec-
trometry.
The solubility of the puri¢ed micro domain, which is in a
denatured form, was poor at neutral pH, but it was soluble in
0.05% TFA (pH 2.3). It has been reported that GC-C binds to
the ligand at pH 4^8 [17]. Therefore, the puri¢ed micro do-
main was refolded by the dilution method under various con-
ditions, followed by altering the solution pH. The puri¢ed
micro domain was dissolved in 0.05% TFA and then mixed
with nine volumes of 50 mM Tris^HCl (pH 7.4) or 50 mM
AcONa (pH 4.7). The micro domain existed as a soluble form
at neutral pH after this procedure as well as under acidic
conditions, implying that the micro domain was folded into
the native conformation.
The ligand-binding ability of the refolded micro domain
was examined using a photoa⁄nity-labeled STa analog, 125I-
ANB-STp(4^17), as shown in Fig. 4A,B. The negative control
in this experiment was performed in the presence of 6 M
guanidine^HCl (pH 7.4) (lanes 1 and 2 in Fig. 4A,B). The
micro domain could not be photoa⁄nity-labeled with 125I-
ANB-STp(4^17) under denaturing conditions, indicating that
non-speci¢c binding was not signi¢cant. However, the re-
folded micro domain, refolded with 50 mM Tris^HCl (pH
7.4), was labeled with 125I-ANB-STp(4^17) and the binding
was speci¢cally inhibited in the presence of unlabeled
STp(4^17) (lanes 3 and 4 in Fig. 4A). Uroguanylin also in-
hibited the binding of 125I-ANB-STp(4^17) to the micro do-
main (lanes 7 and 8 in Fig. 4B). However, the binding ability
of uroguanylin was lower than that of STp(4^17) as well as in
the case of GC-C [18], and uroguanylin could not completely
inhibit the 125I-ANB-STp(4^17) binding to the micro domain
even in the presence of 1035 M uroguanylin (lane 8 in Fig. 4B).
Fig. 2. Curves for the inhibition by STp of the binding of 125I-
ANB-STp(4^17) to wild-type and mutant C349A of ECD. The bind-
ing assay was performed using a previously reported method [14].
ECD, open squares with a dotted line; mutant C349A, open circles
with a solid line.
Fig. 3. SDS^PAGE (A) and HPLC (B) of the micro domain of ECDGCC. A: Proteins were separated on a 15% (w/v) polyacrylamide gel and
visualized by staining with Coomassie brilliant blue: lane 1, total proteins expressed in E. coli cells after induction by IPTG; lane 2, superna-
tant of the cell lysates in lane 1; lane 3, cell lysate precipitates in lane 1; lane 4, the micro domain puri¢ed by HPLC in Fig. 2B. B: The pre-
cipitates in lane 3 were solubilized and treated with Cosmosil 140C18-OPN, as described in Section 2. The resulting materials were dissolved in
50% CH3CN containing 0.05% TFA, and subjected to HPLC. The positions of the micro domain are indicated by arrows. HPLC was per-
formed using a previously reported method [9].
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Since GC-C is able to bind the ligand under acidic conditions
[17], as described above, the ligand-binding ability of the mi-
cro domain was examined under acidic conditions. The re-
folded micro domain, which had been refolded with 50 mM
AcONa (pH 4.7), was also able to bind STp(4^17) at pH 4.7,
but non-speci¢c binding was signi¢cant (lanes 5 and 6 in Fig.
4A,B). These data clearly show that the micro domain pos-
sesses the ability to bind to the ligand.
To estimate the binding capacity of the micro domain, a
competitive binding assay was performed in the presence of
several concentrations of cold STp(4^17) and the ligand-bind-
ing ability was estimated by autoradiographic analysis. Fig. 5
shows the competitive binding curve between the micro do-
main and 125I-ANB-STp(4^17) at equilibrium with an IC50
value of 1U1038 M. This result clearly shows that the micro
domain binds the ligand in the absence of other domains of
GC-C. In order to determine the Kd value of the micro do-
main for ligand binding, we attempted to use a gel ¢ltration
method to separate free and bound ligands, as described in
Section 2. However, it was di⁄cult to completely separate
these peptides. Therefore, it would be necessary to construct
a new assay system for the determination of the Kd value of
the micro domain. However, the binding a⁄nity of the micro
domain was lower than that of ECDGCC (IC50 val-
ue = 1U1039 M) in our assay system, as shown in Fig. 5
[14]. The Kd value of ECDGCC was 4U10310 M, as previ-
ously reported [14]. Therefore, the Kd value of the micro do-
main might be one order lower than that of ECDGCC. The
lower a⁄nity of the micro domain is not dependent on the
lack of the sugar chain at the Asn379 residue, since the pres-
ence of glycosylation at the Asn residue had no e¡ect on the
ligand-binding a⁄nity of ECDGCC [15]. These results indi-
cate that other domains of GC-C may cooperatively aid in
ligand binding at the micro domain. Indeed, a preliminary
structural analysis of the micro domain, based on circular
dichroism (CD) measurements, indicates that the micro do-
main consists of small amounts of K-helix and L-sheet (data
not shown) although the predicted secondary structure is the
L-sheet, suggesting that the micro domain may need assistance
from other domains of GC-C to su⁄ciently fold into the
native conformation so as to bind the ligand.
Previously Nandi et al. reported on the expression of the
N-terminal domain of GC-C by E. coli [19]. They prepared
the entire ECDGCC, including the transmembrane domain,
and a truncated form of ECDGCC, which corresponds to
the region 1^304. They reported that the entire extracellular
domain possessed ligand-binding ability but that the trun-
cated form did not. These results are consistent with the re-
sults reported here, since the micro domain corresponds to the
region Met341^Gln407. Therefore, it can be concluded that
the critical ligand-binding site is located at the micro domain.
The micro domain of ECDGCC corresponds, relatively, to
the region 361^428 of ECDGCA. The putative ANP-binding
sites on GC-A were assigned to regions 173^188 and 191^198
[20]. Although the tertiary structure of GC-C has not yet been
elucidated, ECDGCC might have a tertiary structure similar
to that of ECDGCA. Based on this hypothesis, the identi¢ed
Fig. 4. Autoradiographic analysis of ligand-binding of the micro domain. A: Autoradiography of the micro domain on SDS^PAGE. B: Rela-
tive abundance of the bound ligand was measured by means of a Fujix Bio-image analyzer BAS 2000. The ligand-binding of the micro domain
was examined by photoa⁄nity labeling with 125I-ANB-STp(4^17) in the presence or absence of 1035 M cold STp(4^17) (even- or odd-numbered
lanes in A and B, respectively). The micro domain was refolded in 50 mM Tris^HCl (pH 7.4) containing 6 M guanidine^HCl (lanes 1 and 2),
50 mM Tris^HCl (pH 7.4) (lanes 3, 4, 7, and 8), and 50 mM AcONa (pH 4.7) (lanes 5 and 6) and the binding ability estimated in the same
bu¡er. In lane 8, the binding ability of the micro domain was estimated in the presence of 1035 M uroguanylin. The data present the average
of two data sets.
Fig. 5. Competitive binding assay of the micro domain and
ECDGCC. The curves show the inhibition of binding of 125I-ANB-
STp(4^17) to the refolded micro domain (pH 7.4) (open circles) and
ECDGCC (closed circles) at several concentrations of STp(4^17).
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STa-binding site (Ser387^Lys393) on the micro domain would
be located at the opposite site of the ANP-binding site on the
L-sheet domain of ECDGCA, suggesting that the ligand-bind-
ing site of GC-C is located in a di¡erent region from that of
GC-A or that GC-C may possess another ligand-binding site.
Indeed, the mutant micro domain, in which the Trp392 in the
STa-binding site of the micro domain was mutated to an Ala
residue, showed a lower ligand-binding a⁄nity than that of
the micro domain (data not shown). Therefore, it is possible
that the ligand-binding mode of GC-C may be di¡erent from
that of GC-A.
In conclusion, the micro domain of ECDGCC possesses the
ability to bind ligands in the absence of other domains of GC-
C. This micro domain should be a powerful tool to further
investigate interactions between GC-C and ligands, and will
provide new insights into the signal transduction of GC-C.
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